tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2016 May 16:0. [Epub ahead of print]
[h=1]Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain.[/h] Garc?a A[SUP]1[/SUP], Ortiz de Lejarazu R[SUP]2[/SUP], Reina J[SUP]3[/SUP], Callejo D[SUP]4[/SUP], Cuervo J[SUP]4[/SUP], Morano R[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748 ?/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis show ICER below 30,000?/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.
[h=4]KEYWORDS:[/h] Cost-effectiveness analysis; Costs and cost analysis; Healthcare costs; Human; Influenza; Influenza B virus; Influenza vaccines; QIV; Vaccines
PMID: 27184622 [PubMed - as supplied by publisher]
[h=1]Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain.[/h] Garc?a A[SUP]1[/SUP], Ortiz de Lejarazu R[SUP]2[/SUP], Reina J[SUP]3[/SUP], Callejo D[SUP]4[/SUP], Cuervo J[SUP]4[/SUP], Morano R[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748 ?/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis show ICER below 30,000?/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.
[h=4]KEYWORDS:[/h] Cost-effectiveness analysis; Costs and cost analysis; Healthcare costs; Human; Influenza; Influenza B virus; Influenza vaccines; QIV; Vaccines
PMID: 27184622 [PubMed - as supplied by publisher]